Form 8-K

8-K — BRUKER CORP

Accession: 0001193125-26-207498

Filed: 2026-05-06

Period: 2026-05-06

CIK: 0001109354

SIC: 3826 (LABORATORY ANALYTICAL INSTRUMENTS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — brkr-20260506.htm (Primary)

EX-99.1 (brkr-ex99_1.htm)

GRAPHIC (img53376846_0.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: brkr-20260506.htm · Sequence: 1

8-K

0001109354false00011093542026-05-062026-05-060001109354us-gaap:CommonStockMember2026-05-062026-05-060001109354brkr:SixPointThreeSevenFivePercentageMandatoryConvertiblePreferredStockSeriesAMember2026-05-062026-05-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 6, 2026

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

000-30833

04-3110160

(State or other jurisdiction of

(Commission

(I.R.S. Employer

incorporation)

File number)

Identification No.)

40 Manning Road

Billerica, MA 01821

(Address of principal executive offices) (Zip Code)

(978) 663-3660

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, $0.01 par value per share

BRKR

The Nasdaq Global Select Market

6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value per share

BRKRP

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Section 2 – Financial Information

Item 2.02. Results of Operations and Financial Condition.

On May 6, 2026, Bruker Corporation issued a press release announcing financial results as of and for the three months ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1.

The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information contained in the press release attached hereto as Exhibit 99.1, the press release contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those indicated by these statements. Please refer to the cautionary note contained in the press release under the heading “Forward-Looking Statements” for additional information regarding these forward-looking statements.

Section 9 – Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d)

Exhibits.

Number

Description

99.1

Press release dated May 6, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BRUKER CORPORATION

(Registrant)

Date: May 6, 2026

By:

/s/ GERALD N. HERMAN

Gerald N. Herman

Executive Vice President and Chief Financial Officer

EX-99.1

Filename: brkr-ex99_1.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Bruker Reports First Quarter 2026 Financial Results

•

Q1 2026 revenues of $823.4 million, up 2.7% year-over-year (yoy), down 4.4% organically

•

Q1-26 GAAP diluted earnings per share (EPS) $0.02; non-GAAP diluted EPS $0.31

•

Q1-26 Bruker Scientific Instruments (BSI) bookings up high-single digits % organically yoy;

BSI book-to-bill ratio above 1.0x for 3rd consecutive quarter

•

Reconfirming previous FY2026 guidance:

Revenues of $3.57 to $3.60 billion, up 4% to 5% yoy, with organic growth of 1% to 2%

Non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy, including an ~8% FX headwind

BILLERICA, Massachusetts – May 6, 2026 – Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three months ended March 31, 2026.

Frank H. Laukien, Bruker’s President and CEO, commented: “While US academic demand, tariff and currency headwinds still pressured our first quarter results, our Q1 financial performance came in ahead of expectations. We are encouraged that our first quarter BSI segment bookings grew organically at a high single digit percentage, and our BSI book-to-bill ratio was again greater than 1.0x. Healthy bookings trends included solid academic orders for our post-genomic research solutions from outside the US, strong AI-driven demand in semiconductor metrology and in SciY laboratory software, bookings strength in industrial research tools and security detection systems.”

He continued: “Importantly, we have introduced impactful new products and solutions at recent scientific and medical conferences, further strengthening our leadership position in NMR, leading the way in spatial biology, and innovating in microbiology and molecular diagnostics. With increased visibility, we reconfirm our FY26 guidance, and we expect a return to organic revenue growth in Q2. All in, Bruker remains poised to deliver significant operating margin expansion and double-digit EPS growth in FY2026.”

First Quarter 2026 (Q1-26) Financial Results

Bruker’s revenues for the first quarter of 2026 were $823.4 million, an increase of 2.7% compared to $801.4 million in the first quarter of 2025. In Q1-26, revenues decreased organically by 4.4% yoy, while growth from acquisitions was 2.6%, and foreign currency translation had a favorable impact of 4.5% yoy.

Q1-26 Bruker Scientific Instruments (BSI) revenues of $759.8 million increased 2.1% yoy, with organic revenue decreasing by 5.0%. Q1-26 Bruker Energy & Supercon Technologies (BEST) revenues of $66.9 million increased 12.8% yoy, with an organic revenue increase of 3.0%, net of intercompany eliminations.

Q1-26 GAAP operating income was $10.2 million, compared to GAAP operating income of $31.8 million in the first quarter of 2025. Bruker's Q1-26 non-GAAP operating income was $84.2 million, compared to $101.7 million in the first quarter of 2025, and Q1-26 non-GAAP operating margin was 10.2%, compared to 12.7% in the first quarter of 2025.

Q1-26 GAAP diluted earnings per share was $0.02, compared to diluted earnings per share of $0.11 in the first quarter of 2025. Q1-26 non-GAAP diluted EPS was $0.31, compared to $0.47 in the first quarter of 2025.

Reconfirming Previous Fiscal Year 2026 (FY26) Financial Outlook

Bruker continues to expect FY26 revenues of $3.57 to $3.60 billion, compared to FY25 revenues of $3.44 billion, with 4% to 5% year-over-year reported revenue growth, including:

•

Organic revenue growth of 1% to 2%,

•

M&A revenue growth contribution of approximately 1.5%, and

•

Foreign currency translation revenue tailwind of approximately 1.5%

Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15, compared to $1.83 in FY25, an increase of 15% to 17% year-over-year. This includes a currency headwind of approximately $0.15, or 8%, implying constant exchange rate (CER) non-GAAP EPS growth of 23% to 25% yoy.

Our FY26 revenue and non-GAAP EPS guidance is based on foreign currency exchange rates as of March 31, 2026.

For the Company’s outlook for 2026 organic revenue growth, M&A revenue growth, constant exchange rate revenue growth, and constant exchange rate non-GAAP EPS growth, and non-GAAP EPS, each of which are forward-looking non-GAAP measures, we are not able to provide without unreasonable effort the most directly comparable GAAP financial measures, or reconciliations to such GAAP financial measures on a forward-looking basis. Please see “Use of Non-GAAP Financial Measures” below for a description of items excluded from our expected non-GAAP EPS.

Quarterly Earnings Call

Bruker will host a conference call and webcast to discuss its financial results, business outlook, and related corporate and financial matters today, May 6, 2026, at 8:00 am Eastern Standard Time. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2026 Earnings Webcast” hyperlink. A slide presentation will be referenced during the webcast and will be posted to our Investor Relations website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international) and referencing “Bruker’s First Quarter 2026 Earnings Conference Call”.

Bruker is enabling investors to pre-register for the earnings conference call so that they can expedite their entry into the call and avoid the need to wait for a live operator. In order to pre-register for the call, investors can visit https://dpregister.com/sreg/10208837/103f221d07a and enter their contact information. Investors will then be issued a personalized phone number and PIN to dial into the live conference call. Individuals can pre-register any time prior to the start of the conference call.

A telephone replay of the conference call will be available by dialing 1-855-669-9658 (U.S. toll free) or +1-412-317-0088 (international) and entering replay access code: 6572958. The replay will be available beginning one hour after the end of the conference call through June 6, 2026.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in specialty diagnostics, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Use of Non-GAAP Financial Measures

To supplement our consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (GAAP), we use the following non-GAAP financial measures: non-GAAP gross profit; non-GAAP gross profit margin; non-GAAP operating income; non-GAAP operating income margin; non-GAAP SG&A expense; non-GAAP interest and other income (expense), net; non-GAAP profit before income taxes; non-GAAP income tax rate; non-GAAP net income and non-GAAP diluted earnings per share. These non-GAAP measures exclude costs related to restructuring actions, impairments, acquisition and related integration expenses, amortization of acquired intangible assets, and other non-operational costs.

We also may refer to CER currency revenue growth, CER non-GAAP EPS growth, and free cash flow which are also non-GAAP financial measures. We define the term CER currency revenue as GAAP revenue excluding the effect of changes in foreign currency translation rates. We define the term CER EPS as non-GAAP EPS excluding the effect of changes in foreign currency translation rates. We define free cash flow as net cash provided by operating activities, less additions to property, plant, and equipment. We believe free cash flow is a useful measure to evaluate our business because it indicates the amount of cash generated after additions to property, plant, and equipment that is available for, among other things, acquisitions, investments in our business, repayment of debt and return of capital to shareholders.

The presentation of these non-GAAP financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP and may be different from non-GAAP financial measures used by other companies, and therefore, may not be comparable among companies. We believe these non-GAAP financial measures provide meaningful supplemental information regarding our

performance. However, we urge investors to review the reconciliation of these financial measures to the comparable GAAP financial measures included in the accompanying tables, and not to rely on any single financial measure to evaluate our business. Specifically, management believes that the non-GAAP measures mentioned above provide relevant and useful information which is widely used by analysts, investors and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance.

We use these non-GAAP financial measures to evaluate our period-over-period operating performance because our management believes this provides a more comparable measure of our continuing business by adjusting for certain items that are not reflective of the underlying performance of our business. These measures may also be useful to investors in evaluating the underlying operating performance of our business and forecasting future results. We regularly use these non-GAAP financial measures internally to understand, manage, and evaluate our business results and make operating decisions. We also measure our employees and compensate them, in part, based on certain non-GAAP measures and use this information for our planning and forecasting activities.

Additional information relating to the non-GAAP financial measures used in this press release and reconciliations to the most directly comparable GAAP financial measures are provided in the tables accompanying this press release following our GAAP financial statements.

With respect to our outlook for 2026 non-GAAP organic revenue, non-GAAP M&A revenue, and non-GAAP EPS, we are not providing the most directly comparable GAAP financial measures or corresponding reconciliations to such GAAP financial measures on a forward-looking basis, because we are unable to predict with reasonable certainty certain items that may affect such measures calculated and presented in accordance with GAAP without unreasonable effort. Our expected non-GAAP organic revenue and EPS ranges exclude primarily the future impact of restructuring actions, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments. These reconciling items are uncertain, depend on various factors outside our management’s control and could significantly impact, either individually or in the aggregate, our future revenues and EPS presented in accordance with GAAP.

Forward-Looking Statements

Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our fiscal year 2026 and beyond financial outlook, our outlook for reported revenue growth, organic revenue growth, M&A revenue growth contributions, CER currency revenue growth, margin improvements, foreign currency translation revenue impact, EPS, non-GAAP EPS, and CER Non-GAAP EPS growth; effects of academic market and tariff dynamics on our future financial results and our ability to mitigate such effects in the future; management’s expectations for the impact of foreign currency and acquisitions; the effects of our expanded cost savings initiatives; and for future financial and operational performance and business outlook; future economic conditions; and statements found under the “Use of Non-GAAP Financial Measures” section of this release. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, (1) the length and severity of any recession and the impact on global economic conditions, (2) the impact of supply chain challenges, including inflationary pressures, (3) the impact of geopolitical instability and tensions and any sanctions, including any reduction in natural gas exports from Russia resulting from the ongoing conflict with Ukraine and resulting market disruptions, such as higher prices for and reduced availability of key metals used in our products, (4) the conflict in Israel, Palestine and surrounding areas and hostilities in the Middle East, including heightened tensions in Iran, and the possible expansion of such conflicts and potential geopolitical consequences and global instability, (5) the ongoing tensions between the United States and China, tariff increases or uncertainties and trade policy changes and restrictions, and the increasing potential of conflict involving countries in Asia that are critical to our supply chain operations, such as Taiwan and China, (6) continued volatility in the capital markets, (7) the impact of increased interest rates, (8) the integration and assumption of liabilities of businesses we have acquired or

may acquire in the future, (9) our restructuring and cost-control initiatives, changing technologies, product development and market acceptance of our products, (10) the cost and pricing of our products, manufacturing and outsourcing, competition, dependence on collaborative partners, key suppliers and third party distributors, capital spending and government funding policies, (11) changes in governmental regulations, intellectual property rights, and litigation, (12) exposure to foreign currency fluctuations, (13) the impact of foreign currency exchange rates, (14) our ability to service our debt obligations and fund our anticipated cash needs, (15) the effect of a concentrated ownership of our common stock, (16) the loss of key personnel, (17) payment of future dividends, (18) the impact (if any) of macroeconomic issues, including uncertainties related to trade policies or tariff regulations, and (19) other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2025, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by applicable law.

Contact:

Joe Kostka

Director, Investor Relations

Bruker Corporation

T: +1 (978) 313-5800

E: Investor.Relations@bruker.com

Bruker Corporation

PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

(in millions, except per share data)

Three Months Ended

March 31,

2026

2025

Revenue

823.4

801.4

Cost of revenue

443.6

410.2

Gross profit

379.8

391.2

Operating expenses:

Selling, general and administrative

242.1

225.4

Research and development

101.3

97.1

Other charges, net

26.2

36.9

Total operating expenses

369.6

359.4

Operating income

10.2

31.8

Interest and other income (expense), net

11.7

(6.7

)

Income before income taxes, equity in (losses) income of

unconsolidated investees, net of tax, and noncontrolling

interests in consolidated subsidiaries (a)

21.9

25.1

Income tax provision

2.5

8.7

Equity in (losses) income of unconsolidated investees, net of tax

(3.7

)

0.4

Consolidated net income

15.7

16.8

Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries

1.3

(0.6

)

Net income attributable to Bruker Corporation

14.4

17.4

Dividends on Series A Mandatory Convertible Preferred Stock

10.9

—

Net income attributable to Bruker Corporation common shareholders

3.5

17.4

Net income per common share attributable to Bruker Corporation common shareholders:

Basic

0.02

0.11

Diluted

0.02

0.11

Weighted average common shares outstanding:

Basic

152.2

151.6

Diluted

152.7

151.9

a) On subsequent pages this is referred to as “Profit before income tax”.

Bruker Corporation

REVENUE

(unaudited and in millions)

Three Months Ended

March 31,

2026

2025

Revenue by Segment:

Bruker BioSpin

197.5

207.8

Bruker CALID

316.3

280.1

Bruker Nano

246.0

256.6

BSI Revenue Total

759.8

744.5

BEST

66.9

59.3

Eliminations

(3.3

)

(2.4

)

Total revenue

823.4

801.4

Revenue by End Customer Geography:

United States

221.9

217.4

Europe

321.6

285.2

Asia Pacific

208.7

232.6

Other

71.2

66.2

Total revenue

823.4

801.4

Bruker Corporation

RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES

(unaudited and in millions, except per share data)

The tables below present the GAAP to Non-GAAP reconciliation for the three months ended March 31, 2026, and March 31, 2025, respectively, for the following measures: Gross Profit and Gross Profit Margin; Selling, General and Administrative (“SG&A”) Expenses; Operating Income and Operating Income Margin; Interest and Other Income (Expense), net; Profit before Income Taxes; Net Income Attributable to Bruker Corporation Common Shareholders; Diluted net income per common share; and Income Tax rate.

Gross Profit

Gross Profit Margin

SG&A Expenses

Operating Income

Operating Income Margin

Interest and other income (expense), net

Profit before income tax (a)

Net Income attributable to Bruker Corporation Common Shareholders

Diluted net income per common share

Income Tax Rate

Three Months Ended March 31, 2026:

GAAP

379.8

46.1

242.1

10.2

1.2

11.7

21.9

3.5

0.02

11.4

Non-GAAP adjustments:

Restructuring costs

9.5

1.2

—

17.8

2.2

—

17.8

0.12

—

Acquisition-related costs

3.4

0.4

—

7.5

0.9

—

7.5

0.05

—

Purchased intangibles amortization

16.7

2.0

(15.7

)

32.5

3.9

—

32.5

0.21

—

Intangible assets impairment charges

0.7

0.1

—

2.7

0.3

—

2.7

0.02

—

Gain on remeasurement of previously held equity interest

—

(12.2

)

(12.2

)

(12.2

)

(0.08

)

Investments related adjustments

—

(1.2

)

(1.2

)

(1.2

)

(0.01

)

—

Lease and fixed asset impairment charges

1.8

0.2

—

12.7

1.5

—

12.7

0.08

—

Other costs

(0.1

)

—

0.8

0.2

—

0.8

0.01

—

Tax effect of above Non-GAAP adjustments

—

(20.3

)

(0.13

)

16.2

Equity in income (losses) of unconsolidated investees, net of tax

—

3.7

0.02

—

Noncontrolling interests related to non-GAAP adjustments

—

(0.5

)

—

Total Non-GAAP adjustments

32.0

3.9

(15.7

)

74.0

9.0

(13.4

)

60.6

43.5

0.29

16.2

Non-GAAP

411.8

50.0

226.4

84.2

10.2

(1.7

)

82.5

47.0

0.31

27.6

Three Months Ended March 31, 2025:

GAAP

391.2

48.8

225.4

31.8

4.0

(6.7

)

25.1

17.4

0.11

34.7

Non-GAAP adjustments:

Restructuring costs

2.6

0.3

—

10.2

1.3

—

10.2

0.07

—

Acquisition-related costs

2.3

0.3

—

8.6

1.1

—

8.6

0.06

—

Purchased intangibles amortization

14.0

1.7

(13.1

)

27.3

3.4

—

27.3

0.18

—

Acquisition-related litigation charges

—

18.6

2.3

—

18.6

0.12

—

Investments related adjustments

—

2.0

0.01

—

Other costs

0.8

0.2

—

5.2

0.6

—

5.2

0.03

—

Tax effect of above Non-GAAP adjustments

—

(18.2

)

(0.11

)

(0.6

Other Discrete Items

—

(6.4

Equity in income (losses) of unconsolidated investees, net of tax

—

(0.4

)

—

Total Non-GAAP adjustments

19.7

2.5

(13.1

)

69.9

8.7

2.0

71.9

53.3

0.36

(7.0

Non-GAAP

410.9

51.3

212.3

101.7

12.7

(4.7

)

97.0

70.7

0.47

27.7

(a)

Referred to as “Income before income taxes, equity in (losses) income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries” in the GAAP condensed consolidated statements of operations.

Bruker Corporation

RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES - Continued

(unaudited and in millions, except per share data)

The tables below present the GAAP to Non-GAAP reconciliation for weighted average common shares outstanding (Diluted), CER currency revenue, organic revenue, and free cash flow:

Three Months Ended

March 31,

2026

2025

GAAP Weighted Average Common Shares Outstanding (Diluted)

152.7

151.9

Stock options, restricted stock units, and employee stock purchase plan

—

Series A Mandatory Convertible Preferred Stock (a)

—

Non-GAAP Weighted Average Common Shares Outstanding (Diluted)

152.7

151.9

(a)

The impact of the Series A Mandatory Convertible Preferred Stock (MCP) calculated under the if-converted method was anti-dilutive for both GAAP and Non-GAAP EPS for the three months ended March 31, 2026. There was no MCP outstanding for the comparative period in 2025.

Total Bruker

Bruker Scientific Instruments (a)

BEST

Three Months Ended March 31,

2026

yoy growth (c)

2025

2026

yoy growth (c)

2025

2026

yoy growth (c)

2025

GAAP revenue

823.4

2.7%

801.4

759.8

2.1%

744.5

63.6

11.8%

56.9

Effect of changes in foreign currency translation rates

36.6

(10.4

)

31.6

(9.2

)

5.0

(1.2

)

Non-GAAP CER currency revenue

786.8

(1.8)%

811.8

728.2

(2.2)%

753.7

58.6

3.0%

58.1

Acquisitions (b)

20.8

69.2

20.8

69.2

Non-GAAP Organic revenue

766.0

(4.4)%

742.6

707.4

(5.0)%

684.5

58.6

3.0%

58.1

(a)

Bruker Scientific Instruments (BSI) revenue reflects the sum of the BSI BioSpin, CALID, and NANO Segments as presented in our Annual Report on Form 10-K for the year ended December 31, 2025.

(b)

We define the term acquisitions revenue as GAAP revenue from M&A activities excluding the effect of changes in foreign currency translation rates.

(c)

Yoy growth rates are calculated as the percentage increase (or decrease) in respective line items relative to GAAP revenue in the comparable prior year.

Three Months Ended

March 31,

2026

2025

Net cash provided by operating activities

71.2

65.0

Non-GAAP adjustments:

Purchases of property, plant and equipment

(24.2

)

(26.0

)

Non-GAAP free cash flow

47.0

39.0

Bruker Corporation

PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

(in millions)

March 31,

2026

December 31,

2025

ASSETS

Current assets:

Cash and cash equivalents

133.4

298.8

Accounts receivable, net

542.7

544.9

Inventories

1,121.5

1,094.6

Other current assets

306.0

274.2

Total current assets

2,103.6

2,212.5

Property, plant and equipment, net

719.6

744.8

Goodwill, intangibles, net and other long-term assets

3,307.5

3,284.1

Total assets

6,130.7

6,241.4

LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND

SHAREHOLDERS’ EQUITY

Current liabilities:

Current portion of long-term debt and finance lease obligations

8.4

16.6

Accounts payable

269.1

215.9

Deferred revenue and customer advances

479.7

441.3

Other current liabilities

597.9

605.4

Total current liabilities

1,355.1

1,279.2

Long-term debt

1,662.9

1,852.5

Other long-term liabilities

609.9

599.4

Redeemable noncontrolling interests

35.8

36.8

Total shareholders' equity

2,467.0

2,473.5

Total liabilities, redeemable noncontrolling interests and shareholders' equity

6,130.7

6,241.4

Bruker Corporation

PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

(in millions)

Three Months Ended

March 31,

2026

2025

Cash flows from operating activities:

Consolidated net income

15.7

16.8

Adjustments to reconcile consolidated net income to cash flows from operating activities:

Depreciation and amortization

58.3

50.4

Other non-cash expenses, net

21.4

(11.5

)

Changes in operating assets and liabilities, net of acquisitions and divestitures:

Accounts payable and accrued expenses

11.2

26.4

Inventories

(47.2

)

(28.4

)

Other changes in operating assets and liabilities, net

11.8

11.3

Net cash provided by operating activities

71.2

65.0

Cash flows from investing activities:

Purchases of property, plant and equipment

(24.2

)

(26.0

)

Cash paid for acquisitions, net of cash acquired

(16.0

)

(1.1

)

Other investing activities, net

0.5

1.0

Net cash used in investing activities

(39.7

)

(26.1

)

Cash flows from financing activities:

Repayments of revolving lines of credit

—

(167.9

)

Proceeds from revolving lines of credit

—

139.9

Repayment of long-term debt

(181.3

)

(7.7

)

Proceeds from long-term debt

—

2.9

Payment of dividends to Series A Mandatory Convertible Preferred Shareholders

(11.0

)

—

Payment of dividends to common shareholders

(7.6

)

(7.7

)

Repurchase of common stock

—

(10.0

)

Other financing activities, net

(5.0

)

(0.7

)

Net cash used in financing activities

(204.9

)

(51.2

)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

7.9

13.3

Net increase (decrease) in cash, cash equivalents and restricted cash

(165.5

)

1.0

Cash, cash equivalents and restricted cash at beginning of period

303.1

186.7

Cash, cash equivalents and restricted cash at end of period

137.6

187.7

GRAPHIC

Filename: img53376846_0.jpg · Sequence: 3

Binary file (19541 bytes)

Download img53376846_0.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Document and Entity Information

May 06, 2026

Entity Listings [Line Items]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 06, 2026

Entity Registrant Name

BRUKER CORPORATION

Entity Central Index Key

0001109354

Entity Incorporation State Country Code

Entity File Number

000-30833

Entity Tax Identification Number

04-3110160

Entity Address, Address Line One

40 Manning Road

Entity Address, City or Town

Billerica

Entity Address, State or Province

Entity Address, Postal Zip Code

01821

City Area Code

978

Local Phone Number

663-3660

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Common Stock

Entity Listings [Line Items]

Security 12b Title

Common Stock, $0.01 par value per share

Trading Symbol

BRKR

Security Exchange Name

NASDAQ

6.375% Mandatory Convertible Preferred Stock, Series A

Entity Listings [Line Items]

Security 12b Title

6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value per share

Trading Symbol

BRKRP

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_EntityListingsLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=brkr_SixPointThreeSevenFivePercentageMandatoryConvertiblePreferredStockSeriesAMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: